In the Spotlight...
Oncogenic Kras targeting with MRTX1133 or Daraxonrasib specifically synergize with anti-CTLA4 to promote anti-tumor immunity in pancreatic cancer
The Dendritic Cell-based Vaccine PROTEXI leverages Antiviral CD4 T cell Memory to boost anti-tumor immune responses in mice
Tumor-induced dendritic cell deregulation perturbs T cell proliferation and predicts clinical outcome in acute lymphoblastic leukemia
Spatial biology reveals altered macrophage states in immunosuppressed non-melanoma skin cancer
Previous Digests
Helpers don’t clock out: CD4s essential for both priming and effector phases of ICB
August 5, 2026
While CD4+ T cells are crucial for CD8+ T cell priming in ICB-induced antitumor responses, their helper role at the effector phase remains largely unknown. Ameh et al. used murine MHC-II- sarcoma models to study CD4+ T cell help...
cDC1s serve as architects for the formation and maintenance of tumoral TLSs
July 29, 2026
The presence of tertiary lymphoid structures (TLSs) in tumors is associated with improved outcomes and response to immune checkpoint blockade (ICB). Although the cell populations within these TLSs are well established, the precise contributions of DCs to TLS formation...
CARM1 inactivation in cDC1s completes the antitumor trifecta
July 22, 2026
Coactivator-associated arginine methyltransferase (CARM1) is an epigenetic enzyme that controls transcription by methylating arginine residues of chromatin-associated proteins. In previous research, deletion or inhibition of CARM1 in tumor cells enhanced their IFNγ production and sensitized them to T cell-mediated...
Watch ACIR in action
In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.
Watch the 3-minute video explaining ACIR's mission and goal:
In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.
Watch the 6-minute segment on the story behind your favorite digest here:
About ACIR
ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.
Ute Burkhardt
Ed Fritsch
Lauren Hitchings
Gaëlle Llambi
Maartje Wouters
Alex Najibi
Katherine J. Turner
Stan Wolf
Paula Hochman
Shishir Pant
Nathan Suek
Morgan Janes
TESTIMONIALS
I'm a big fan of ACIR. I enjoy their weekly newsletters with clear, concise, and insightful summaries, complemented by excellent images. I've even used the images in some of my presentations to explain complex cancer immunotherapy findings. In our rapidly evolving field, their reliable and well-curated updates are invaluable.
Richard W. Vague Professor in Immunotherapy; Professor of PL&M; Director, Center for Cellular Immunotherapies; Director, Parker Institute for Cancer Immunotherapy; University of Pennsylvania Perelman School of Medicine. (Supporter since 2025).
Current Sponsors
